FLASHBACK: Hedgeye Says Buy Exact Sciences | $EXAS

05/31/17 11:07AM EDT

Shares of Exact Sciences (one of our healthcare team's favorite longs) have surged over 10% today. The stock soared after UnitedHealth Group said it plans to cover the company's colon cancer test starting on July 1. EXAS was targeted by short-seller Citron Research earlier this month -- one of the short-seller's allegations was that UnitedHealth Group wouldn't ever cover the test. 

Here's our response to Citron Research earlier this month.

https://twitter.com/KeithMcCullough/status/869915814127960068

Here's our Sector Head Tom Tobin discussing our long call back in January. The stock is up 100% since then.

https://youtu.be/9nIkHepvk-w

© 2024 Hedgeye Risk Management, LLC. The information contained herein is the property of Hedgeye, which reserves all rights thereto. Redistribution of any part of this information is prohibited without the express written consent of Hedgeye. Hedgeye is not responsible for any errors in or omissions to this information, or for any consequences that may result from the use of this information.